Research Analysts’ Recent Ratings Changes for Compass Therapeutics (CMPX)

Several brokerages have updated their recommendations and price targets on shares of Compass Therapeutics (NASDAQ: CMPX) in the last few weeks:

• 2/8/2026 – Compass Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 2/4/2026 – Compass Therapeutics was given a new $13.00 price target on by analysts at Canaccord Genuity Group Inc..
• 1/31/2026 – Compass Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 1/21/2026 – Compass Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/17/2026 – Compass Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 1/6/2026 – Compass Therapeutics had its “outperform” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $9.00 price target on the stock.
• 1/6/2026 – Compass Therapeutics had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
• 1/5/2026 – Compass Therapeutics is now covered by analysts at William Blair. They set an “outperform” rating on the stock.

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.